0 69

Cited 0 times in

Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study

 Junsik Park  ;  Se Ik Kim  ;  Soo Young Jeong  ;  Yup Kim  ;  Michael A Bookman  ;  Jae-Weon Kim  ;  Byoung-Gie Kim  ;  Jung-Yun Lee 
 GYNECOLOGIC ONCOLOGY, Vol.165(1) : 97-104, 2022-04 
Journal Title
Issue Date
BRCA1 Protein / genetics ; BRCA2 Protein / genetics* ; Carcinoma, Ovarian Epithelial / drug therapy ; Carcinoma, Ovarian Epithelial / genetics ; Disease Progression ; Female ; Humans ; Maintenance Chemotherapy ; Mutation ; Neoplasm Recurrence, Local / drug therapy ; Ovarian Neoplasms* / drug therapy ; Ovarian Neoplasms* / genetics ; Ovarian Neoplasms* / pathology ; Phthalazines ; Piperazines ; Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use ; Poly(ADP-ribose) Polymerases ; Retrospective Studies
Carcinoma ; Olaparib ; Ovarian Epithelial ; Ovarian neoplasms ; Prognosis ; Recurrence ; Survival
Introduction: With expanded use of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi), there is a potential impact of PARPi resistance on platinum resistance. A post-hoc analysis of SOLO2 demonstrated a reduction in response to subsequent platinum-based therapy among patients who received prior olaparib but not placebo. The present multicentre, retrospective, observational study was conducted to determine the effects of olaparib on subsequent therapy for recurrent epithelial ovarian cancer (EOC).

Materials and methods: Data on EOC patients with BRCA1/2-mutated tumours who received second-line platinum-based chemotherapy between January 2012 and June 2020, at three South Korean institutions (n = 197) were collected. Patients who received olaparib as maintenance therapy after second-line chemotherapy were assigned to the olaparib group (n = 105), and subjects who did not receive olaparib maintenance therapy were assigned to the control group (n = 92). The primary endpoint was time intervals from the date of second disease progression (PFS1) to the date of third disease progression (PFS2), expressed as PFS2 - PFS1.

Results: As expected, PFS1 in the olaparib group was longer than the control group. However, PFS2 - PFS1 in the olaparib group was significantly shorter than that of the control group (median 7.9 vs. 13.6 m; p = 0.0005). Even when the third-line PARPi maintenance (cross-over) patients were excluded from the control group, the response to subsequent therapy in the olaparib group remained poor (median 7.7 vs. 11.5; p = 0.0422).

Discussions: Patients with platinum-sensitive BRCA1/2 mutated tumours who progressed during olaparib maintenance after second-line chemotherapy were less likely to respond to third-line chemotherapy compared to controls who did not receive olaparib, suggesting that resistance to olaparib may contribute to chemotherapy resistance.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yup(김엽)
Park, Junsik(박준식)
Lee, Jung-Yun(이정윤) ORCID logo https://orcid.org/0000-0001-7948-1350
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.